Breast Cancer | Specialty

Neoadjuvant Therapy in HER2+ Breast Cancer

March 29th 2019

Adjuvant Therapy for HR+ Breast Cancer

March 29th 2019

Genomic Testing & Adjuvant Therapy in HR+ Breast Cancer

March 29th 2019

CDK4/6 Inhibitors: Treating Beyond Progression

March 29th 2019

Selecting a CDK4/6 Inhibitor in HR+ Breast Cancer

March 29th 2019

Managing CDK4/6 Inhibitor Adverse Events

March 29th 2019

CDK4/6 Inhibitor Toxicity in HR+ Breast Cancer

March 29th 2019

CDK4/6 Inhibitors for HR+ Breast Cancer

March 29th 2019

Fulvestrant/Anastrozole Combo Improves Survival in Metastatic HR+ Breast Cancer

March 29th 2019

The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.

Promising Findings Pave Way for Patients With TNBC

March 28th 2019

Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.

Dr. Euhus on the Rarity of Angiosarcoma of the Breast

March 28th 2019

David M. Euhus, MD, director of breast surgery, professor of surgery, Johns Hopkins Medicine, discusses the rarity of angiosarcoma of the breast.

FDA Proposes Policy Changes to Improve Mammography Quality Standards

March 28th 2019

The FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services, in order to enable healthcare providers and patients to make more informed medical decisions

Progress Continues in HR+/HER2- Breast Cancer Paradigm

March 26th 2019

Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.

Dr. Hunt on Treating Local Regional Recurrence in Breast Cancer

March 26th 2019

Kelly Hunt, MD, professor and chair of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with breast cancer who have local regional recurrence.

Using Recurrence Risk to Tailor Treatment in HR+/HER2- Breast Cancer

March 25th 2019

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

Expert Addresses Therapeutic Updates for Breast Cancer Subtypes

March 22nd 2019

William J. Gradishar, MD, discusses the latest updates in HER2-negative advanced breast cancer and the role of molecular assays in this space.

Dr. Ward on Multigene Testing in Breast Cancer

March 22nd 2019

​​John H. Ward, MD, discusses his preferences in multilane testing for patients with hormone receptor–positive, node-negative breast cancer.

Dr. Rao on Treatment De-Escalation in HR+/HER2- Breast Cancer

March 20th 2019

Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.

For This Giant of Cancer Care, a Holistic Approach Was Always in the Treatment Plan

March 20th 2019

A 2018 Giants of Cancer Care® award winner for Supportive, Palliative Geriatric Care, Patricia A. Ganz, MD has spent much of her life working to improve the quality of care for patients with cancer.

When a Measure of Significance Is Not All That Significant

March 20th 2019

The term statistically significant is almost certainly beautiful music to the ears of clinical investigators and pharma/biotech companies. However, concern develops when one inquires how the most common test of significance, the P value, is used in clinical investigative efforts and whether at times this is more harmful than helpful within the domain of cancer medicine.